Company intelligence / Profile preview

Taichengsi (Shanghai) Biopharmaceutical

Shanghai, Shanghai Shi, China

Ownership: Private
Development stage: Other

Overview

Taichengsi is developing preclinical antibody-drug conjugates and monoclonal antibodies targeting Claudin 6 and other tumor-associated proteins, primarily for cancer indications; no clinical results reported as of July 2025

Therapeutic areas: OncologyEndocrinologyHematologyGastroenterology
Modalities: Antibody-drug conjugateMonoclonal antibody
Industry: Biotech

Partnerships

No public partnerships with major pharmaceutical companies disclosed as of July 2025

Beyond the preview

Go deeper on Taichengsi (Shanghai) Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taichengsi (Shanghai) Biopharmaceutical.

Explore the full profile